Teladoc, Inc. (NYSE:TDOC) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, July 25th.
Other research analysts have also issued reports about the company. Canaccord Genuity reiterated a “buy” rating and set a $34.00 price target on shares of Teladoc in a report on Wednesday, May 24th. Robert W. Baird reiterated a “buy” rating and set a $28.00 price target on shares of Teladoc in a report on Tuesday, May 9th. Chardan Capital upped their price target on Teladoc from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Piper Jaffray Companies reiterated a “buy” rating and set a $32.00 price target on shares of Teladoc in a report on Friday, July 14th. Finally, TheStreet upgraded Teladoc from a “d” rating to a “c-” rating in a report on Thursday, April 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $35.55.
Shares of Teladoc (NYSE TDOC) traded down 1.14% during mid-day trading on Tuesday, hitting $30.35. 682,680 shares of the stock traded hands. The stock’s market cap is $1.72 billion. Teladoc has a one year low of $14.00 and a one year high of $36.90. The stock has a 50-day moving average of $33.88 and a 200 day moving average of $27.52.
Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter last year, the firm earned ($0.38) earnings per share. The firm’s quarterly revenue was up 68.3% compared to the same quarter last year. Equities analysts predict that Teladoc will post ($1.47) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/12/bidaskclub-downgrades-teladoc-inc-nysetdoc-to-hold-updated-updated.html.
In other Teladoc news, VP Mark Hirschhorn sold 100,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $27.70, for a total value of $2,770,000.00. Following the transaction, the vice president now owns 80,887 shares of the company’s stock, valued at $2,240,569.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the transaction, the insider now directly owns 33,008 shares in the company, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. Insiders sold 207,186 shares of company stock worth $6,122,950 over the last quarter. Company insiders own 5.94% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can raised its position in Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock worth $123,000 after buying an additional 2,397 shares in the last quarter. Pacad Investment Ltd. acquired a new position in Teladoc during the second quarter worth approximately $135,000. Great West Life Assurance Co. Can acquired a new position in Teladoc during the first quarter worth approximately $105,000. US Bancorp DE raised its position in shares of Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after buying an additional 433 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Teladoc during the second quarter valued at about $166,000. 95.88% of the stock is currently owned by institutional investors.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.